

Reports of Table2

Ipidacrine[1]

Ursolic-acid[2-5]

Wortmannin[6, 7]

Thapsigargin[8-10]

Reports of Table3

AZD-6482[11]

vorinostat[12-14]

1. Liu, Y., et al., *COVID-19 Multi-Targeted Drug Repurposing Using Few-Shot Learning*. Front Bioinform, 2021. **1**: p. 693177.
2. Al-Kuraishy, H.M., et al., *Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective*. Inflammopharmacology, 2022. **30**(5): p. 1493-1501.
3. Al-Kuraishy, H.M., A.I. Al-Gareeb, and G. El-Saber Batiha, *The possible role of ursolic acid in Covid-19: A real game changer*. Clin Nutr ESPEN, 2022. **47**: p. 414-417.
4. Shree, P., et al., *Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study*. J Biomol Struct Dyn, 2022. **40**(1): p. 190-203.
5. Mpiana, P.T., et al., *Oleanolic Acid, Ursolic Acid and Apigenin from Ocimum basilicum as Potential Inhibitors of the SARS-CoV-2 Main Protease: A Molecular Docking Study*. International Journal of Pathogen Research, 2021: p. 1-16.
6. Selvaraj, G., et al., *Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches*. F1000Res, 2021. **10**: p. 127.
7. Jiang, Y., et al., *Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid*. Comput Biol Med, 2022. **146**: p. 105601.
8. Al-Beltagi, S., et al., *Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus*. Viruses, 2021. **13**(2).
9. Al Otaibi, A., et al., *Thapsigargin and Tunicamycin Block SARS-CoV-2 Entry into Host Cells via Differential Modulation of Unfolded Protein Response (UPR), AKT Signaling, and Apoptosis*. Cells, 2024. **13**(9).
10. Shaban, M.S., et al., *Multi-level inhibition of coronavirus replication by chemical ER stress*. Nat Commun, 2021. **12**(1): p. 5536.

11. Günther, S., et al., *X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease*. Science, 2021. **372**(6542): p. 642-646.
12. Das, S., K. Camphausen, and U. Shankavaram, *In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data*. Res Sq, 2020.
13. Adhami, M., et al., *Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis*. BMC Biotechnol, 2021. **21**(1): p. 22.
14. Takahashi, Y., et al., *Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19*. Sci Rep, 2021. **11**(1): p. 3379.